Patient, disease, and donor characteristics
Characteristics . | Values . |
|---|---|
| Median age, y (range) | 51 (20-66) |
| Sex, no. (%) | |
| Male | 42 (59) |
| Female | 29 (41) |
| Disease diagnosis, no. (%) | |
| AML FAB M1 | 13 (18) |
| AML FAB M2 | 16 (23)* |
| AML FAB M3 | 1 (1)* |
| AML FAB M4 | 16 (23) |
| AML FAB M5 | 16 (23) |
| AML FAB M6 | 3 (4) |
| AML unclassified | 6 (8) |
| Secondary AML | 17 (24) |
| Karyotype | |
| Good prognosis | 5 (7)† |
| Standard risk | 47 (66) |
| Poor prognosis | 17 (24) |
| Not available | 2 (3) |
| Disease status at transplantation, no. (%) | |
| Complete remission | 36 (51) |
| First CR | 22 (31) |
| Second CR | 14 (20) |
| Non-CR | 35 (49) |
| Untreated primary disease | 1 (1) |
| Untreated relapse | 7 (10) |
| Refractory disease | 27 (38) |
| Primary induction failure | 15 (21) |
| Refractory relapse | 12 (17) |
| Median time from diagnosis to transplantation, mo. (range) | 6 (1-54) |
| Patients considered ineligible for conventional conditioning by main exclusion criteria, no. (%) | 63 (87) |
| Age, older than 60 y | 11 (16) |
| Invasive fungal infection | 27 (38) |
| Severe infections during prior therapy | 8 (11) |
| Multiple therapies prior to transplantation | 2 (3) |
| Prior autograft/allograft‡ | 10 (14) |
| Organ dysfunction/prior organ toxicity | 5 (7) |
| Recipient CMV positive, no. (%) | 44 (62) |
| Donor characteristics, no. (%) | |
| HLA-identical sibling | 38 (54) |
| Mismatched sibling | 1 (1) |
| Matched unrelated, 10/10 HLA match | 22 (31) |
| Mismatched unrelated, 9 or fewer/10 HLA match | 10 (14) |
| Source of stem cells, no (%) | |
| PBSCs | 68 (96) |
| BM | 3 (4) |
| Median no. CD34+ cells infused × 106/kg (range) | 7.2 (1.8-15.9) |
Characteristics . | Values . |
|---|---|
| Median age, y (range) | 51 (20-66) |
| Sex, no. (%) | |
| Male | 42 (59) |
| Female | 29 (41) |
| Disease diagnosis, no. (%) | |
| AML FAB M1 | 13 (18) |
| AML FAB M2 | 16 (23)* |
| AML FAB M3 | 1 (1)* |
| AML FAB M4 | 16 (23) |
| AML FAB M5 | 16 (23) |
| AML FAB M6 | 3 (4) |
| AML unclassified | 6 (8) |
| Secondary AML | 17 (24) |
| Karyotype | |
| Good prognosis | 5 (7)† |
| Standard risk | 47 (66) |
| Poor prognosis | 17 (24) |
| Not available | 2 (3) |
| Disease status at transplantation, no. (%) | |
| Complete remission | 36 (51) |
| First CR | 22 (31) |
| Second CR | 14 (20) |
| Non-CR | 35 (49) |
| Untreated primary disease | 1 (1) |
| Untreated relapse | 7 (10) |
| Refractory disease | 27 (38) |
| Primary induction failure | 15 (21) |
| Refractory relapse | 12 (17) |
| Median time from diagnosis to transplantation, mo. (range) | 6 (1-54) |
| Patients considered ineligible for conventional conditioning by main exclusion criteria, no. (%) | 63 (87) |
| Age, older than 60 y | 11 (16) |
| Invasive fungal infection | 27 (38) |
| Severe infections during prior therapy | 8 (11) |
| Multiple therapies prior to transplantation | 2 (3) |
| Prior autograft/allograft‡ | 10 (14) |
| Organ dysfunction/prior organ toxicity | 5 (7) |
| Recipient CMV positive, no. (%) | 44 (62) |
| Donor characteristics, no. (%) | |
| HLA-identical sibling | 38 (54) |
| Mismatched sibling | 1 (1) |
| Matched unrelated, 10/10 HLA match | 22 (31) |
| Mismatched unrelated, 9 or fewer/10 HLA match | 10 (14) |
| Source of stem cells, no (%) | |
| PBSCs | 68 (96) |
| BM | 3 (4) |
| Median no. CD34+ cells infused × 106/kg (range) | 7.2 (1.8-15.9) |
FAB indicates French-American-British; CMV, cytomegalovirus; PBSCs, peripheral blood stem cells; and BM, bone marrow.
Of the 16 patients with AML FAB M2, 5 received a transplant in CR1 (2 with secondary AML), 4 in CR2, 7 with non-CR. The patient with AML FAB M3 was in second CR
Four patients in second CR; one additional patient with complex karyotype and t(8;21) in first CR but with early relapse after transplantation
One patient with prior allograft